Business
Grace Therapeutics, Inc.: We may not be able to maintain our operations and advance our research and development and commercialization of our GTx-104 lead drug candidate without additional funding.
Net income increased 25.6% to ($9.6M), while Operating cash flow decreased 20.8% to ($14.9M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($9.6M)Watch
- Cash generation — Free cash flow ($14.9M)Note
- Accounting — Formula-grey distress score · manipulation and earnings-quality screens not computedNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-28
- DEF 14A · Annual proxy (pay & governance)2026-07-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Grace Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.